Abstract
Prokinetic agents are a very large family of drugs with different mechanisms of action. Only QT prolongation by cisapride has made notable impact and deserved its partial restriction and/or withdrawal from the market. Postmarketing surveillance initially showed that cisapride was generally safe and well tolerated, but in the past decade, more recent data have shown some risk in the patient populations. QT prolongation by prokinetic agents can raised from different mechanisms: some involve increased plasma concentrations of cisapride due to increased bioavailability by inhibiting P glycoprotein, and inhibition of metabolism or deficit in the elimination. On the other hand, pharmacodynamic interactions can also enhance the arrhythmogenic effect of cisapride. The present article presents the mechanisms and reviews the main interactions studied so far, and the role of pharmacovigilance in the detection of rare clinical events. We emphasize the need for physicians to look for conditions (either clinical or not) prone to increase the risk of QT interval prolongation.
Keywords: Prokinetic agents, cisapride, mosapride, torsades de pointes, long QT syndrome, pharmacovigilance
Current Drug Safety
Title: Prokinetic Agents and QT Prolongation: A Familiar Scene with New Actors
Volume: 5 Issue: 1
Author(s): Guillermo Alberto Keller and Guillermo Di Girolamo
Affiliation:
Keywords: Prokinetic agents, cisapride, mosapride, torsades de pointes, long QT syndrome, pharmacovigilance
Abstract: Prokinetic agents are a very large family of drugs with different mechanisms of action. Only QT prolongation by cisapride has made notable impact and deserved its partial restriction and/or withdrawal from the market. Postmarketing surveillance initially showed that cisapride was generally safe and well tolerated, but in the past decade, more recent data have shown some risk in the patient populations. QT prolongation by prokinetic agents can raised from different mechanisms: some involve increased plasma concentrations of cisapride due to increased bioavailability by inhibiting P glycoprotein, and inhibition of metabolism or deficit in the elimination. On the other hand, pharmacodynamic interactions can also enhance the arrhythmogenic effect of cisapride. The present article presents the mechanisms and reviews the main interactions studied so far, and the role of pharmacovigilance in the detection of rare clinical events. We emphasize the need for physicians to look for conditions (either clinical or not) prone to increase the risk of QT interval prolongation.
Export Options
About this article
Cite this article as:
Keller Alberto Guillermo and Di Girolamo Guillermo, Prokinetic Agents and QT Prolongation: A Familiar Scene with New Actors, Current Drug Safety 2010; 5 (1) . https://dx.doi.org/10.2174/157488610789869166
DOI https://dx.doi.org/10.2174/157488610789869166 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Triggers and Anatomical Substrates in the Genesis and Perpetuation of Atrial Fibrillation
Current Cardiology Reviews Airway Management During Pediatric Resuscitation
Current Pediatric Reviews Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity
Current Topics in Medicinal Chemistry Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Current Drug Targets It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Metabolomics of Serum Peptides
Protein & Peptide Letters Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety Depressive Illness and Emotional Learning
Current Medical Imaging Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Management of Acute Aluminum Phosphide Poisoning: Has Anything Changed?
Drug Metabolism Letters Chromogranins and Inositol 1,4,5-Trisphosphate-Dependent Ca2+-Signaling in Cardiomyopathy and Heart Failure
Current Medicinal Chemistry Post Cardiovascular Surgery Atrial Fibrillation. Biomarkers Determining Prognosis
Current Medicinal Chemistry Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Current Medicinal Chemistry Inhaled Corticosteroids in COPD: Pros and Cons
Current Drug Targets ACE Inhibitor Delapril Prevents Ca<sup>2+</sup>-Dependent Blunting of I<sub>K1</sub> and Ventricular Arrhythmia in Ischemic Heart Disease
Current Molecular Medicine Synthesis and Biological Activity of the Pyridine-hexacyclic-steroid Derivative on a Heart Failure Model
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Practical Considerations in the Development of Hemoglobin-Based Oxygen Therapeutics
Current Drug Discovery Technologies